Abstract Proliferating cell nuclear antigen (PCNA) is a late growth-regulated gene that is expressed at the Gl-S boundary of the cell cycle and is required for DNA synthesis and cell proliferation. Since quantitative results suggest that myocyte hyperplasia occurs in the decompensated human heart, we postulated that induction of the PCNA gene may be present in the failing heart in humans. PCNA protein was detected in myocardial samples obtained from the left and right ventricles of patients with congestive heart failure. Endomyocardial biopsies collected from donor subjects were used as control tissue. The percentage of positively stained myocyte nuclei in the ventricles was established by using PCNA monoclonal antibody and the immunoperoxidase technique. The localization of PCNA in myocytes was confirmed by a-sarcomeric actin antibody staining. PCNA labeling was present in left ventricular myocytes of 29 of the 32 hearts examined. In the right ventricle, 24 of the 29 samples showed positive staining. In a subset of 25 patients, the percentage of PCNA-labeled myocyte nuclei was measured and found to constitute 49±22% of left ventricular myocytes. A similar analysis for the right here are several gene products that are required for cell proliferation. 
of the cell cycle and is required for DNA synthesis and cell proliferation. Since quantitative results suggest that myocyte hyperplasia occurs in the decompensated human heart, we postulated that induction of the PCNA gene may be present in the failing heart in humans. PCNA protein was detected in myocardial samples obtained from the left and right ventricles of patients with congestive heart failure. Endomyocardial biopsies collected from donor subjects were used as control tissue. The percentage of positively stained myocyte nuclei in the ventricles was established by using PCNA monoclonal antibody and the immunoperoxidase technique. The localization of PCNA in myocytes was confirmed by a-sarcomeric actin antibody staining. PCNA labeling was present in left ventricular myocytes of 29 of the 32 hearts examined. In the right ventricle, 24 of the 29 samples showed positive staining. In a subset of 25 patients, the percentage of PCNA-labeled myocyte nuclei was measured and found to constitute 49±22% of left ventricular myocytes. A similar analysis for the right here are several gene products that are required for cell proliferation.1 Proliferating cell nuclear antigen (PCNA), a cofactor of DNA polymerase delta,23 is a nuclear protein necessary for DNA synthesis and for cell cycle progression.1 When cells are in GO, PCNA mRNA levels are low but rapidly increase in the presence of growth factors, stimulating cells to divide. 45 In continually dividing cells, PCNA mRNA and the protein itself vary little in amount throughout the cell cycle. 6 The crucial role of PCNA for cell growth has been documented by inhibition of cell proliferation by an antisense oligodeoxynucleotide to PCNA mRNA.78 Under these conditions, cell growth is abolished. Thus, the induction of PCNA protein in myocytes may be considered an important indicator that these cells may enter the cell cycle and undergo DNA synthesis and nuclear mitotic division. This contention is supported by the observation that PCNA protein has ventricle, conducted in 21 patients, showed that 49±19% of the myocyte nuclei exhibited PCNA protein. In addition, mitotic figures in myocytes were documented. A quantitative analysis of this cellular process revealed that 11 myocyte nuclei per 1 million cells exhibited mitotic images in chronic heart failure. Immediately after myocardial infarction, two cells per million showed mitotic division, and this phenomenon was restricted to the region adjacent to the necrotic tissue. No PCNA labeling or nuclear mitotic images were detected in the ventricular myocardium of control subjects. Thus, the observation that diffuse PCNA labeling and myocyte mitotic division are present in hearts with end-stage failure strongly suggests that adult ventricular myocytes are not terminally differentiated cells and that myocyte cellular hyperplasia may constitute a growth reserve mechanism of the diseased heart. (Circ Res. 1994;75:1050-1063.) Key Words * late growth-related genes * myocyte nuclear mitotic division * myocyte hyperplasia * end-stage cardiac failure * human heart been detected in ventricular myocytes of the mammalian rat heart during embryonic and early postnatal life,9 during which myocyte cellular hyperplasia predominates. 10 In contrast, PCNA protein has not been demonstrated in normal adult ventricular myocytes, in spite of the fact that PCNA mRNA is present.9 However, in pathological states characterized by severe ventricular dysfunction and failure, the expression of PCNA mRNA is markedly enhanced in association with the appearance of PCNA protein in the stressed myocytes.11,12 DNA synthesis, myocyte mitotic division, and myocyte cellular hyperplasia have been documented as well.12-14 These experimental observations constituted the basis for the present investigation, in which the hypothesis was advanced that activation of late growthregulated genes may occur in the failing human heart. Specifically, the induction of PCNA protein in myocytes was examined in samples of ventricular myocardium from patients undergoing cardiac transplantation. Although the identification of PCNA protein in these cells may provide supporting evidence that adult ventricular myocytes are not terminally differentiated cells, it cannot be determined from this phenomenon whether the activation of the DNA synthetic machinery actually results in myocyte nuclear mitotic division. Therefore, a careful analysis of the occurrence of mitosis in myocytes was performed and compared with the magnitude of this cellular process in the fetal human heart. An identical evaluation was conducted at the level of the nonmyocyte compartment of the myocardium. This type of determination is without precedent in humans and animal models in both normal conditions and pathological states of the heart. Moreover, mitotic images in myocytes of the adult human heart have never been identified.
Materials and Methods

Cardiac Function and Ventricular Anatomy
The hemodynamic and gross anatomic properties of the hearts included in the present study were established between 1 and 6 months before cardiac transplantation. Specifically, measurements of systolic and diastolic ventricular dimensions and fractional shortening were performed by two-dimensional echocardiography.15 Stroke volume, cardiac output, cardiac index, ejection fraction, right ventricular end-diastolic pressure, and pulmonary wedge pressure were determined by cardiac catheterization. 16 Tissue Fixation and Sampling Thirty-two hearts were sampled immediately after cardiectomy from patients undergoing cardiac transplantation at the De Gasperi Division of Cardiac Surgery in Milan. Specimens were obtained from the left and right ventricular myocardium and fixed in 10% buffered formalin. These tissue fragments were taken halfway between the base and the apex in the subendocardial-midmyocardial region of the anterior wall of each ventricle. Technical limitations did not permit fixation of all samples for an identical time period. Twenty-five of the 32 left ventricular specimens and 22 of the 29 right ventricular samples were uniformly fixed for 30 minutes and used for the quantitative analysis of PCNA distribution in myocytes. The remaining cases were used for qualitative detection of PCNA in the myocardium but were excluded from the quantitative determinations. To ensure rapid and adequate fixation, the initial specimens were cut into small tissue blocks, 2 to 3 mm3 in size, which were embedded in paraffin for light microscopy. Five to 25 tissue samples were obtained in each case in each ventricle.
Four additional left ventricular samples were collected at autopsy from four patients who died within 5 days after acute myocardial infarction and intractable congestive heart failure. These patients were included since tissue fragments became available within 2 hours after death. However, they were used only for qualitative detection of PCNA protein in the tissue and for a careful search of mitotic figures in the myocardium.
Endomyocardial biopsies performed before cardioplegic arrest in five donor subjects were used as control tissue for PCNA localization. By this approach, only a limited number of tissue fragments were collected, and sampling was restricted to the right ventricle. In spite of these limitations, this myocardium was considered to represent the most appropriate control for baseline PCNA immunohistochemistry. Finally, three fetal hearts were obtained within 5 to 10 hours from abortion and treated in a similar manner for the detection of PCNA protein in ventricular cells and analysis of the number of mitotic divisions in the myocardium.
PCNA Localization
Immunohistochemical staining was performed by using a modification of the immunoperoxidase method of Hsu et al. 17 The monoclonal mouse antibody anti-PCNA (PC10, Dako A/S) was used for this study. The specificity of this antibody has been established previously.18 Five-micrometer-thick sections were rehydrated in phosphate-buffered saline (PBS) and then exposed to 3% hydrogen peroxide for 5 minutes to block endogenous peroxidase activity. Subsequently, the sections were treated with normal serum to quench nonspecific protein binding. The antibody, diluted 1:100 with PBS, 1% bovine serum albumin, and 0.1% sodium azide, was applied for 10 minutes at room temperature. Sections were then subjected to two-step incubations of 10 minutes each with biotinylated antiserum followed by peroxidase-labeled streptavidin (commercial kit, Dako LSAB). Finally, the sections were counterstained with Mayer's hematoxylin and mounted with glycerol gelatin. Negative controls in which PBS replaced the primary antiserum were performed with each batch of stains. Lymph node sections were used as positive controls.
After the qualitative detection of PCNA labeling in the myocardium, the percentage of positively stained myocyte nuclei was determined in both ventricles at a final magnification of x400. This analysis was achieved by examining an average of 600 myocyte nuclei in each ventricle in each case.
The distinction between myocyte nuclei and nonmyocyte nuclei could not be performed in the fetal myocardium. Nuclei are closely adjacent to each other and are surrounded by a small amount of cytoplasm, which makes the recognition of the cell of origin often uncertain. Therefore, the extent of PCNA labeling in these cases was measured in relation to all cell populations. This determination included the analysis of 4500 to 5000 nuclei per heart.
a-Sarcomeric Actin Staining
To demonstrate further that PCNA protein labeling occurred in adult ventricular myocyte nuclei, sections from a limited number of samples were stained first for PCNA by using alkaline phosphatase-labeled streptavidin (commercial kit, Dako LSAB/R) and fast red chromogen (Biogenex). Subsequently, sections were incubated for 10 minutes with monoclonal anti-rabbit sarcomeric actin antibody (Dako-sarcomeric actin, Alpha-Sr-1) diluted 1:40, followed by peroxidase-labeled streptavidin. As a chromogen, 3-amino-9-ethylcarbazole was used. By this approach, PCNA-labeled nuclei appeared reddish, and a-sarcomeric actin staining of the cytoplasm appeared brownish. In the fetal myocardium, a more complete type of analysis was performed because the availability of the entire heart allowed the estimation of the total number of mitotic figures in myocytes, nonmyocytes, and nonidentifiable cells in the whole organ. Four different steps were involved in these determinations: First, the percentage of mitotic figures in each of these cell groups was established as described above. The magnitude of sampling involved in this quantitative aspect varied from 2.42 to 3.11 mm2. Mitotic images in the different cell populations were expressed in relation to the total nuclear counts per unit area of myocardium, since the distinction between myocyte and nonmyocyte nuclei was difficult. Second, average nuclear length was determined by measuring midsections of 1000 nuclei per heart at a magnification of x 1250 by using a methodology previously described. '4,19 The quotient between the number of nuclei per unit area of myocardium, N(n)A, and the average nuclear length, Dn, allowed the computation of the number of nuclei per unit volume of myocardium, N(n)v:
(1)
Third, this parameter, N(n)v, multiplied by the aggregate volume of the heart, obtained from the quotient of heart weight and the specific gravity of muscle tissue, 1.06 g/mL,20
VT, allowed the determination of the total number of nuclei in the heart, N(n)T:
Finally, the product of the percentage of mitotic images in myocytes and the total number of nuclei yielded the aggregate number of mitotic figures in myocytes in the entire heart. An identical calculation was applied for the other cell populations.
Statistical Analysis
Data were collected blindly, and the code was broken at the end of the study. Results are presented as mean±SD. Statis 
Results
Patient Population
The present study was performed by using myocardial samples from 32 patients who underwent cardiac transplantation and from 4 patients who died shortly after acute myocardial infarction and intractable congestive heart failure. Tissue specimens were obtained from the latter 4 patients within 2 hours after death. Right ventricular endomyocardial biopsies, collected from 5 donor subjects before cardioplegic arrest and removal of the heart, were used as control myocardium. The entire population included only white individuals.
The myocardial samples obtained from the explanted hearts were collected during a period of 10 months, from April 1992 to February 1993, at the De Gasperi Division of Cardiac Surgery in Milan. No preoperative criteria were established in the selection of the cases. Only two additional hearts became available during this period, but they were excluded since one was a transplanted heart with late graft failure and the second was not properly treated for PCNA protein detection. This approach was followed in order to include all patients with congestive heart failure regardless of the etiology of the process, sex, age, and the therapeutic treatment.
Five samples of normal myocardium were collected from four males who died of cranial trauma and one female who died of spontaneous cerebral hemorrhage. Hearts were eligible for homograft transplant so that only small biopsy specimens from the right ventricle could be obtained. The age of these patients varied from 18 to 53 years (average, 35 years). Anatomic and Functional Characteristics Table 1 shows that of the 36 patients involved, there were 14 with idiopathic dilated cardiomyopathy, 17 with ischemic heart disease, and 5 with acquired valvular defects. Age, sex, duration of the disease process, and the time interval between the occurrence of heart failure (New York Heart Association [NYHA] class 3) and cardiac transplantation are also listed in Table 1 . With the exception of the 4 patients for whom samples were collected at autopsy and for whom no data were available, 26 patients were in NYHA functional class 4, and 6 patients were in NYHA functional class 3. At the time of surgery, 24 patients were under intravenous inotropic therapy, and 2 patients needed a ventricular assistance device.
Although the left ventricle was the most affected site in 12 of the 14 patients with idiopathic dilated cardiomyopathy, the right ventricle was the primary site of localization in 2 of the patients. Moreover, for one of these 2 patients, left ventricular function was maintained, whereas in the other, a depressed left-side performance was documented. Left ventricular assistance was required in 2 patients for 2 and 46 days before transplantation.
With one exception, the 17 patients in the ischemic cardiomyopathic group had a history of myocardial infarction. Coronary angiography showed three-vessel disease in 6 patients, two-vessel disease in 2 patients, one-vessel disease in 3 patients, and essentially normal coronary arteries in another patient. In one instance, coronary angiography was not performed, but a large aneurysmatic dilation of the left ventricle was present. In the patient with normal coronary arteries, the primary event was an anterior myocardial infarction, which occurred during pregnancy, =13 years before transplantation. In the 4 patients for whom samples were collected at autopsy, extensive acute myocardial infarction was present. In addition, 3 patients showed marked biventricular hypertrophy, which was associated with aneurysms of the ascending and abdominal aorta in one patient and severe and diffuse atherosclerosis of the coronary arteries in the others.
In the valvular heart disease group, two of the five patients had involvement of the mitral and aortic valves, two had involvement of the mitral valve only, and the last had a defect restricted to the aortic valve. This subdivision corresponds to the initial diagnosis. All five individuals had valve replacement during the course of the disease. Table 2 presents measurements of cardiac hemodynamics and anatomic properties collected 1 to 6 months before cardiac transplantation. These data show a marked reduction in the ejection fraction coupled with a significant increase in left ventricular diastolic and systolic diameters. These changes produced a severe decrease in fractional shortening, which was found to be comparable in the three groups of patients. In addition, the ratio of wall thickness to chamber radius was reduced, and left ventricular end-diastolic volume was nearly doubled in all cases. Finally, the cardiac index was depressed, and pulmonary wedge pressure was elevated. Right ventricular end-diastolic pressure was lower in the group with ischemic cardiomyopathy.
PCNA Labeling of the Ventricular Myocardium
The distribution of PCNA protein in the myocardium was detected by the immunoperoxidase technique. Sections from lymph nodes were used as controls for the immunohistochemical reaction. The myocardial samples obtained from the right ventricle of control hearts showed no PCNA labeling in myocyte and nonmyocyte nuclei. In contrast, labeling was found in myocyte nuclei and other cell types of the left and right ventricles of patients affected by end-stage cardiac failure. Similarly, PCNA protein was detected in myocytes located in the proximity of the infarcted tissue of the four hearts collected at autopsy. Extensive search in the left ventricular tissue remote from the infarction failed to reveal positively stained myocyte nuclei. In addition, no PCNA staining was observed in the right ventricle of these hearts. PCNA labeling was also observed in the three fetal hearts examined. These cells were all located in the proximity of the infarction, whereas mitosis was never seen in the myocardium, distant from the necrotic zone.
Mitotic figures were also found in myocardial samples obtained from patients undergoing cardiac transplantation. Such an image, in which metaphase chromosomes in the center of a transversely sectioned myocyte profile were noted, is shown in Fig 4. There is no difficulty in recognizing the cell of origin in this case, which belonged to a patient affected by dilated cardiomyopathy.
An approach identical to that described above for the localization of PCNA protein was followed here for the identification and confirmation of mitotic figures in myocytes. Fig 5 demonstrates Table 5 shows the quantitative analysis performed to evaluate the total number of nuclei present in the three fetal hearts obtained for this investigation. This information, combined with the evaluation of the number of mitotic images in myocytes. nonmyocytes. and nonidentifiable cells, allowed the computation of the total number of mitotic figures in the heart for each of these three classes of cells. Table 6 shows an analysis similar to that described above for the fetal heart for 7 of the 25 patients undergoing cardiac transplantation in whom mitotic images in the left ventricle were found. However, the distinction between myocyte and nonmyocyte nuclei was possible in the well-differentiated adult heart, so the parameters of myocyte nuclear density and nonmyocyte nuclear density in the myocardium were obtained. By counting 27 452 myocyte nuclei and 78 167 nonmyocyte nuclei in 106 mm2 of myocardium, the numerical density of myocyte nuclei and nonmyocyte nuclei per square millimeter of tissue was measured. Myocytes were found to possess a nuclear numerical density that was 66% (P<.0001) lower than that of nonmyocytes. These values were the bases for the subsequent calculations listed in Table 6 .
To identify mitotic images in myocytes, an average of 425 mm2 of myocardium had to be examined in each case. This amount of sampling was 28-fold greater than that used for the estimation of the nuclear density of myocytes and nonmyocytes listed in Table 6 . In addition, it is important to recognize that the frequency of mitotic figures in tissue sections for any cell type is dependent on its nuclear density in the myocardium. Therefore, the product of the number of nuclei per unit area of myocardium and the area of myocardium sampled for the detection of mitotic figures yielded the aggregate number of nuclei examined for each cell population. By this approach, the percentage of myocyte nuclei and nonmyocyte nuclei showing mitotic images was obtained and is listed last in Table 6 . Fig 8 illustrates the number of mitotic figures in each cell group per 106 nuclei. This analysis showed that the frequency of mitotic images in myocyte nuclei was 1.71-fold greater than that in nonmyocyte nuclei, and this difference was statistically significant (P<.05). In addition, mitoses in myocytes were 3.20-fold more numerous than in nonidentifiable cells, and this value was also statistically significant (P<.001). Finally, it should be recognized that when all cell populations are considered, the examination of 1 000 000 nuclei in the myocardium will yield two or three mitotic images in myocyte nuclei.
As discussed in the preceding section, parameters identical to those described above could not be obtained in the fetal myocardium. Therefore, a direct comparison between the fetal and failing heart was not possible. Table 6 would be =59 000. Since left and right ventricular weights are nearly equal in the fetal heart, the total number of left ventricular myocyte nuclei in mitosis would be 86 500. Thus, the fetal left ventricle appears to exhibit 47% more mitotic images than the adult failing left ventricle. Table 7 shows the area of myocardium examined and the number of nuclei counted to estimate the myocyte and nonmyocyte nuclear numerical density in the tissue of four patients who died of congestive heart failure shortly after coronary artery occlusion. These data, in combination with the numbers of mitotic figures in myocytes and nonmyocytes encountered in a larger area of myocardium, were used to compute the percentage of myocyte and nonmyocyte nuclei undergoing mitosis. Since mitotic images were not observed in the myocardium remote from the infarct, this analysis was restricted to the surviving tissue contained within the first 5 to 10 mm lateral to the necrotic region. Fig 9 illustrates that for every 106 myocyte nuclei, two muscle cell nuclei exhibited mitotic figures. The frequency of mitosis in nonmyocyte nuclei was of the same magnitude and was also limited to the peri-infarcted zone of viable myocardium. Thus, in the period immediately following infarction, mitosis of myocytes and nonmyocytes was significantly less frequent than in chronic heart failure and did not involve the portion of the ventricle distant from the damaged tissue.
Incidence of Mitotic Figures Immediately After Myocardial Infarction
Discussion
The results of the present study indicate that endstage cardiac failure is characterized by the induction of PCNA protein in myocytes biventricularly. This response involved >40% of the myocyte population and was not disease dependent, being comparable in idiopathic dilated cardiomyopathy, chronic coronary artery disease, and valvular heart disease. PCNA labeling was also present in the other cell populations of the myocardium, including smooth muscle cells, endothelial cells, and fibroblasts. In addition, mitotic images in myocyte and nonmyocyte nuclei were found in the myocardium of both ventricles. Importantly, a quantitative analysis of the frequency of mitosis in myocyte nuclei of the failing left ventricle documented that this cellular process was only 32% lower than that measured in the fetal heart. Similarly, myocyte nuclear mitotic divisions were seen in the viable tissue after acute myocardial infarction. However, in the latter condition, mitosis in myocytes was restricted to the region bordering the infarct, and its magnitude was significantly less than that detected in chronic heart failure. Finally, the incidence of mitosis in myocyte nuclei was equal to or greater than that in the other cell populations of the ventricular myocardium. In contrast, no PCNA protein or mitotic images were detected in myocytes and connective tissue cells from normal hearts. Thus, the abnormalities in hemodynamic load generated by a prolonged impairment in ventricular pump function appear to be coupled with the activation of a late growthrelated gene, which is essential for DNA synthesis and cell cycle progression. This phenomenon, in combination with the presence of myocyte nuclear mitotic division, strongly supports the notion that ventricular myocytes are not terminally differentiated cells. Growth-Regulated Genes and the Mammalian Heart PCNA and histone-H3 are late growth-regulated genes that are expressed at the Ga-S phase boundary.23'24 These genes are responsible for the progression of the cell cycle and nuclear mitotic division. 2, 3, 7, 8 of PCNA-stained myocytes,27 which represents one fifth of the magnitude of labeling documented in this investigation. Thus, the induction of the PCNA gene appears to be coupled with pathological states of the heart and particularly with the abnormalities in ventricular loading generated by intractable congestive heart failure. Whether aging may participate in the activation of this system cannot be excluded, since myocyte mitotic division and cellular hyperplasia have been shown to occur experimentally in the senescent myocardium.19'28 Moreover, myocyte nuclear and possibly cellular hyperplasia has been documented in elderly patients affected by severe cardiac decompensation. 29 The percentage of myocyte and nonmyocyte nuclei showing PCNA labeling in the fetal heart was similar to that detected in myocardial samples from patients undergoing cardiac transplantation. However, the fraction of nuclei exhibiting mitosis in the fetal heart was severalfold greater than in the adult myocardium. This difference is difficult to explain, although the possibility may be advanced that the lengths of the S, G2, and M phases of the cell cycle are not comparable in the fetal and adult ventricular tissue, influencing the relative number of PCNA-labeled cells. The lower mitosis-to-PCNA-labeled nuclei ratio in the adult heart most likely reflects a markedly longer myocyte cell cycle. Although it is a common assumption that the extent of proliferation in interstitial cells is significantly greater than in myocytes, results in the present study indicate that the mitotic index was higher in myocyte than in nonmyocyte nuclei of the failing heart. However, this information does not take into account the total number of endothelial cells and fibroblasts in the myocardium that exceed the aggregate number of myocytes. In addition, the duration of the cell cycle may differ among these three cell populations. Finally, the activation of connective tissue cell proliferation may occur at different times during the evolution of the cardiomyopathic heart of ischemic and nonischemic origin. The present data simply indicate that a large sampling is required not only for the detection of mitosis in myocytes but also for the identification of this process in endothelial cells and fibroblasts.
Difficulties exist in the evaluation of myocyte cellular hyperplasia by various methodologies. So far, quantitative measurements of myocyte nuclei in the ventricle, combined with the evaluation of the distribution of nuclei in myocytes, appear to be the only approach that can demonstrate myocyte cellular hyperplasia unequivocally.14"19 However, the concomitant presence of myocyte loss and myocardial damage complicates this type of analysis.14"9 Autoradiographic detection of thymidine-labeled tissue has also been used to establish whether DNA synthesis and cellular hyperplasia occur in myocytes.35 '38 On the other hand, it is impossible by this technique to distinguish whether DNA synthesis in nuclei is due to nuclear hyperplasia, ploidy formation, or DNA repair. Since myocardial damage and diffuse and segmental cell loss are common findings in the failing human heart, the approach followed here, in which the presence of a nuclear protein essential for the initiation of DNA synthesis and cell cycle progression was demonstrated in combination with mitotic division, may offer the advantage of documenting an important molecular event involved in cell proliferation. Myocyte Cellular Hyperplasia and the Mammalian Heart
The possibility that myocyte cellular hyperplasia may contribute to the hypertrophic growth of the myocardium in pathological states of the heart remains controversial. It is a general belief that once myocyte proliferation ceases shortly after birth in the mammalian heart, physiological and induced postnatal myocardial growth occur principally through hypertrophy of myocytes. In contrast, a hyperplastic component persists in interstitial fibroblasts and capillary endothelial cells, which, in combination with cellular hypertrophy, participate in the expansion of the overloaded myocardium.26 These conclusions have been based on a limited number of studies performed in animal models of pressure-overload hypertrophy in which little38 or no43 thymidine labeling has been found in the stressed myocardium. De novo DNA synthesis was seen to be restricted mostly to the nonmyocyte populations of the ventricle, suggesting the absence of myocyte cellular hyperplasia during the development and progression of cardiac hypertrophy.38 '43 Although the observations above support the concept of the inability of cardiac muscle cells to divide, it has been demonstrated recently that myocyte cellular hyperplasia can occur in the left and right ventricular myocardium in association with a prolonged and sustained elevation in workload on the heart'4,44-47 or with aging and senescence. '1928,29,47 In addition, DNA synthesis in myocyte nuclei has been found immediately after myocardial infarction13,48 and after coronary artery constriction.12'14 These experimental findings appear to confirm quantitative results obtained in the human heart that strongly indicate the occurrence of myocyte proliferation with severe degrees of cardiac hypertrophy.2931-34 It should be emphasized, however, that documentations consistent with myocyte regeneration were obtained only in the presence of profound alterations in ventricular pump function and congestive heart failure in both humans29,31-34 and animals.11-1419,46-48 Thus, activation of the replicatory machinery of adult human cardiac myocytes may occur exclusively in response to the marked abnormalities in myocardial loading encountered in the failing heart. In contrast, cellular hypertrophy may be the dominant growth mechanism of the stressed myocardium in its compensated stage.
Limitations of the Study and Conclusions
There are several limitations in the present investigation that must be acknowledged. The observations of PCNA protein immunostaining in myocytes and nuclear mitotic division cannot be interpreted as unequivocal indicators of myocyte cellular hyperplasia. As stated previously, the lack of information concerning the duration of the cell cycle and the time necessary for mitosis to occur does not permit a correlation between the degree of PCNA labeling and the fraction of myocytes entering the S phase and subsequently dividing. Moreover, PCNA may lead to DNA synthesis, but this process may be coupled with polyploidization or DNA repair.1928'404' In this regard, a large fraction of nuclei in the hypertrophied human heart have been found to be polyploid.49 '50 Since the destiny of mitotic cells is not known, the possibility cannot be excluded that mitosis of differentiated cardiac muscle cells is accompanied by nuclear fragmentation and cell death. Similarly, nuclear mitotic division may result in multinucleation of cells without cell division. '14'1928,44-48 It should be emphasized, however, that the number of myocyte nuclei per cell tends to decrease in cardiac failure experimentally.14"19 Myocyte nuclear mitotic division12"3'28 results consistently in myocyte cellular hyperplasia.14"9 On the other hand, with the exception of the fetal heart, the morphometric approach used examined enough myocardium to obtain one myocyte nuclear mitotic image in each case. This type of analysis may reflect an underestimation of the real magnitude of this phenomenon in the heart or an overestimation. Nevertheless, additional work for a more precise characterization of the phenomenon of mitosis in the human heart does not appear justified. Variability in the duration of the disease, medical history, diet, smoking habits, and living conditions may contribute significantly to the large standard deviation of the mean values obtained here. Since, by definition, cells terminally differentiated cannot reenter the cell cycle and undergo nuclear mitotic division, the present that adult ventricular myocytes in humans do not belong to this class of cells.
